Jasper Therapeutics sees a stock boost after sickle cell data release; Newron lifts the veil on data for schizophrenia treatment
Jasper Therapeutics is having a good start to the new year as it unveils data from its Phase I/II trial investigating the addition of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
